electroCore (NASDAQ:ECOR) Earns “Buy” Rating from HC Wainwright

electroCore (NASDAQ:ECOR)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 92.31% from the company’s previous close.

electroCore Price Performance

NASDAQ ECOR opened at $13.00 on Thursday. The company’s 50 day simple moving average is $16.16 and its two-hundred day simple moving average is $12.26. electroCore has a 1 year low of $5.32 and a 1 year high of $19.49. The stock has a market capitalization of $86.53 million, a PE ratio of -7.10 and a beta of 0.24.

Hedge Funds Weigh In On electroCore

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ECOR. Geode Capital Management LLC boosted its position in shares of electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after acquiring an additional 5,951 shares during the last quarter. HighTower Advisors LLC bought a new stake in electroCore during the third quarter valued at approximately $255,000. Jane Street Group LLC purchased a new position in electroCore in the 4th quarter worth approximately $278,000. JPMorgan Chase & Co. increased its holdings in shares of electroCore by 31,250.0% in the 4th quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock worth $61,000 after buying an additional 3,750 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of electroCore in the 4th quarter worth $438,000. 26.74% of the stock is currently owned by hedge funds and other institutional investors.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.